BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26717194)

  • 1. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?
    Brierley CK; Steensma DP
    Curr Opin Hematol; 2016 Mar; 23(2):167-74. PubMed ID: 26717194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
    Oran B
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S43-9. PubMed ID: 26297277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
    Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
    Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?
    de Witte TM; Bowen D; Robin M; Malcovati L; Mufti G; Niederwieser D; Yakoubagha I; Kröger N;
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S42-5. PubMed ID: 25486954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?
    Wermke M; Gloaguen S; Platzbecker U
    Curr Hematol Malig Rep; 2015 Sep; 10(3):329-33. PubMed ID: 26126601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.
    Yahng SA; Kim M; Kim TM; Jeon YW; Yoon JH; Shin SH; Lee SE; Eom KS; Lee S; Min CK; Kim HJ; Kim DW; Lee JW; Min WS; Kim YJ
    Oncotarget; 2017 Feb; 8(7):12342-12354. PubMed ID: 27729615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
    Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
    J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome.
    Radujkovic A; Becker N; Benner A; Penack O; Platzbecker U; Stölzel F; Bornhäuser M; Hegenbart U; Ho AD; Dreger P; Luft T
    Oncotarget; 2015 Oct; 6(33):35095-106. PubMed ID: 26360778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemopoietic cell transplantation for the myelodysplastic syndromes.
    Scott BL; Deeg HJ
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes.
    Kim Y; Kim IH; Kim HJ; Park S; Lee KH; Kim SJ; Lee JH; Kim DY; Yoon SS; Kim YK; Jang JH; Park SY; Ahn JS; Cheong CW; Lee JH; Cheong JW;
    Int J Hematol; 2014; 99(5):635-43. PubMed ID: 24648120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
    Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.
    Bhatt VR; Steensma DP
    J Oncol Pract; 2016 Sep; 12(9):786-92. PubMed ID: 27621329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes.
    Bart-Smith E; Mufti GJ
    Curr Opin Oncol; 2014 Nov; 26(6):642-9. PubMed ID: 25208055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplant strategies for patients with myelodysplastic syndromes.
    Deeg HJ
    Curr Opin Hematol; 2006 Mar; 13(2):61-6. PubMed ID: 16456370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions.
    Warlick ED
    Curr Opin Oncol; 2010 Mar; 22(2):150-4. PubMed ID: 20010295
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Shallis RM; Podoltsev NA; Gowda L; Zeidan AM; Gore SD
    Expert Rev Hematol; 2020 May; 13(5):447-460. PubMed ID: 32182435
    [No Abstract]   [Full Text] [Related]  

  • 19. Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2.
    Chen Y; Huang F; Xuan L; Zhang Y; Fan Z; Xu N; Zhao K; Xu J; Liu H; Shi P; Wang Z; Sun J; Zheng W; Dai M; Liu Q
    Int J Cancer; 2021 Sep; 149(5):1109-1120. PubMed ID: 33899230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of induced therapy before allogeneic hematopoietic stem-cell transplantation for higher-risk myelodysplastic syndrome: experience of single centre].
    Zhou JY; He GS; Wu DP; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu ZZ; Ma X; Miao M; Xue SL; Wang Y
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3185-8. PubMed ID: 24405537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.